Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verrica Pharmaceuticals reports strong Q3 revenue growth and promising therapies

Verrica Pharmaceuticals' Q3 performance reflects strong revenue generation from YCANTH and promising developments in novel therapies like VP-315.
While facing challenges in market clearance efforts and significant SG&A costs, the company's strategic initiatives position it for future growth.
Opportunities lie in expanding market presence, optimizing costs, and protecting intellectual property to drive profitability and innovation.

Verrica Pharmaceuticals reports robust Q4 earnings and eyes regulatory milestones

Verrica Pharmaceuticals showcased strong financial performance with $1.9 million in YCANTH net revenue and 94% gross margins for 2023.
Strategic partnerships, pipeline advancements, and progress in eliminating market challenges position the company for future growth.
Challenges in sampling activity, revenue forecasting, and regulatory uncertainties require careful navigation for sustained success.
Opportunities in distribution expansion, revenue optimization, and regulatory advancements offer avenues for continued development and success.

Verrica Pharmaceuticals excels in Q1 with strong revenue growth

Verrica Pharmaceuticals demonstrated strong performance in Q1 2024 with significant revenue generation and pipeline advancements.
While facing financial challenges and uncertainties, the company's strategic strengths and opportunities position it well for future growth.
Addressing cost management, market integrity, and maximizing revenue potential will be crucial for sustaining profitability and market leadership.

Verrica Pharmaceuticals excels in Q2, eyes market expansion opportunities

Verrica Pharmaceuticals' Q2 performance reflects strong revenue growth and promising developments in product pipelines. While challenges exist in accelerating demand and maintaining profitability, the company's strategic focus on partnerships and market optimization positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica's Compensation Committee granted David Zawitz, Verrica's new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company's Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz's employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4).

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum (“molluscum”) in Japan.

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and accompanying Series A and Series B warrants (or $0.8899 per pre-funded warrant and accompanying Series A and Series B warrants). All of the securities being sold in the offering are being sold by Verrica. The offering is expected to close on November 22, 2024, subject to the satisfaction of customary closing conditions. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares of the Company's common stock and/or Series A warrants to purchase up to 3,540,000 additional shares of its common stock and Series B warrants to purchase up to 3,540,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Verrica Announces Pricing of $42.0 Million Public Offering

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the proposed offering will be sold by Verrica. Verrica intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants to purchase shares of its common stock in an amount up to 15% of the securities offered in the public offering under the same terms and conditions. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Verrica Announces Proposed Public Offering

SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2021 and 2022 to secure regulatory approval for its drug product VP-102, designed to treat molluscum. Current shareholders are encouraged to contact the firm.

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA). In December 2020, the Company submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for regulatory approval of its lead product, VP-102 or YCANTH, for the treatment of molluscum contagiosum, a skin disea.

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists   WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH ® for the treatment of molluscum contagiosum.

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

NEW ORLEANS , Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director, LifeSci Advisors Ted White - President and Chief Executive Officer Joe Bonaccorso - Chief Commercial Officer Terry Kohler - Chief Financial Officer Gary Goldenberg - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Serge Belanger - Needham Kemp Dolliver - Brookline Capital Markets Operator Good morning, and welcome to the Verrica Pharmaceuticals Second Quarter 2024 Earnings Conference Call.

Verrica Pharmaceuticals, Inc. (VRCA) Q2 2024 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.21 per share a year ago.

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates

- Reports YCANTH ® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor –

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to continue to grow due to aging US population, better diagnosis and increased exposure to risk factors WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) --  Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced preliminary positive results from Part 2 of its Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

AirSculpt Technologies

Kadant

Mondee Holdings Inc

scPharmaceuticals

Trupanion

Westrock Coffee Holdings LLC

Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it's a showdown between the bears that are attempting to profit from the downturn of a public enterprise.

7 Short-Squeeze Stocks That Could Beat Down the Bears

- Dormer Labs has discontinued the sale of  all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City.

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025

Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Chris Calabrese - MD, LifeSci Advisors Ted White - President & CEO Joe Bonaccorso - CCO Terry Kohler - CFO Gary Goldenberg - CMO Chris Hayes - Chief Legal Officer Conference Call Participants Stacy Ku - TD Cowen Anish Nikhanj - RBC Capital Markets Glen Santangelo - Jefferies Oren Livnat - H.C. Wainwright Serge Belanger - Needham and Company Kemp Dolliver - Brookline Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Verrica Pharmaceuticals First Quarter 2024 Earnings Conference Call.

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.13 per share a year ago.

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

– Reports YCANTH® revenue of $3.2M for first quarter of 2024  – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2024.

Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results

WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals' President and Chief Executive Officer, will present at the following investor conferences:

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.

Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Verrica Pharmaceuticals Inc Stock (VRCA)